Which agents are associated with increased risk of sarcomas in childhood leukemia? What are the most common secondary cancers among survivors of childhood leukemias, lymphomas, and other childhood malignancies? Take this multiquestion quiz to find out.
How much do you understand about evaluating prognosis and choosing treatment for patients with myeloma? Take our latest quiz to find out.
Umbralisib, a dual inhibitor of PI3Kδ and casein kinase-1Ɛ, was well tolerated and showed early signs of clinical activity in a phase I lymphoma study.
In a Canadian survey, lung cancer patients were more likely to report that they should be asked about their smoking status at every clinic visit.
In a study of over 100,000 adults, overall cancer risk, particularly of breast cancer, was associated with dietary intake of ultra-processed foods.
FL progression risk at 2 years was twice as high in the high-risk vs the low-risk group, and the gene-expression score may help to guide treatment.
Adjuvant platinum-based chemotherapy is associated with delayed metastasis among patients diagnosed with upper-tract urothelial carcinoma, according to findings from the phase III POUT trial.
Pazopanib was not associated with prolonged progression-free survival compared with temsirolimus among patients with advanced clear-cell renal cell carcinoma, but a subgroup analysis of intermediate-risk patients offered some reason for optimism.
Adjuvant therapy with sunitinib after nephrectomy was associated with increased mortality among older women with renal cell carcinoma, according to a subgroup analysis of data from the ASSURE trial.
Combining axitinib and pembrolizumab is “safe and tolerable” among patients with previously untreated advanced renal cell carcinoma, with 73% of patients responding, according to findings from an open-label, phase Ib trial.